生物工程非编码RNA制剂（BERA）在发挥作用。
Bioengineered non-coding RNA agent (BERA) in action.
作者信息
Duan Zhijian, Yu Ai-Ming
机构信息
a Department of Biochemistry & Molecular Medicine , Comprehensive Cancer Center, UC Davis School of Medicine , Sacramento , CA , USA.
出版信息
Bioengineered. 2016 Nov;7(6):411-417. doi: 10.1080/21655979.2016.1207011. Epub 2016 Jul 14.
Abstract
Non-coding RNAs (ncRNAs) including microRNAs (miRNAs) and small interfering RNAs (siRNAs) are important players in the control of gene regulation and represent novel promising therapeutic targets or agents for the treatment of various diseases. While synthetic ncRNAs are predominately utilized, the effects of excessive artificial modifications on higher-order structures, activities and toxicities of ncRNAs remain uncertain. Inspired by recombinant protein technology allowing large-scale bioengineering of proteins for research and therapy, efforts have been made to develop practical and effective means to bioengineer ncRNA agents. The fermentation-based approaches shall offer biological ncRNA agents with natural modifications and proper folding critical for ncRNA structure, function and safety. In this article, we will summarize current recombinant RNA platforms to the production of ncRNA agents including siRNAs and miRNAs. The applications of bioengineered ncRNA agents for basic research and potential therapeutics are also discussed.
摘要
包括微小RNA（miRNA）和小干扰RNA（siRNA）在内的非编码RNA（ncRNA）是基因调控控制中的重要参与者，并且是治疗各种疾病的新型有前景的治疗靶点或药物。虽然主要使用合成ncRNA，但过度人工修饰对ncRNA的高级结构、活性和毒性的影响仍不确定。受允许对蛋白质进行大规模生物工程用于研究和治疗的重组蛋白技术的启发，人们已努力开发实用且有效的方法来对ncRNA药物进行生物工程改造。基于发酵的方法应能提供具有天然修饰且折叠正确的生物ncRNA药物，这对ncRNA的结构、功能和安全性至关重要。在本文中，我们将总结当前用于生产包括siRNA和miRNA在内的ncRNA药物的重组RNA平台。还将讨论生物工程改造的ncRNA药物在基础研究和潜在治疗方面的应用。
相似文献
1
Bioengineered non-coding RNA agent (BERA) in action.生物工程非编码RNA制剂（BERA）在发挥作用。
Bioengineered. 2016 Nov;7(6):411-417. doi: 10.1080/21655979.2016.1207011. Epub 2016 Jul 14.
2
Bioengineering of noncoding RNAs for research agents and therapeutics.用于研究试剂和治疗的非编码RNA的生物工程。
Wiley Interdiscip Rev RNA. 2016 Mar-Apr;7(2):186-97. doi: 10.1002/wrna.1324. Epub 2016 Jan 13.
3
Bioengineering of a single long noncoding RNA molecule that carries multiple small RNAs.单个长非编码 RNA 分子的生物工程，该分子携带多个小 RNA。
Appl Microbiol Biotechnol. 2019 Aug;103(15):6107-6117. doi: 10.1007/s00253-019-09934-5. Epub 2019 Jun 11.
4
Single bioengineered ncRNA molecule for dual-targeting toward the control of non-small cell lung cancer patient-derived xenograft tumor growth.单个生物工程 ncRNA 分子用于双重靶向控制非小细胞肺癌患者来源异种移植肿瘤生长。
Biochem Pharmacol. 2021 Jul;189:114392. doi: 10.1016/j.bcp.2020.114392. Epub 2021 Jan 3.
5
Novel approaches for efficient in vivo fermentation production of noncoding RNAs.新型高效非编码 RNA 体内发酵生产方法。
Appl Microbiol Biotechnol. 2020 Mar;104(5):1927-1937. doi: 10.1007/s00253-020-10350-3. Epub 2020 Jan 17.
6
Expression and Purification of tRNA/ pre-miRNA-Based Recombinant Noncoding RNAs.基于tRNA/前体微小RNA的重组非编码RNA的表达与纯化
Methods Mol Biol. 2021;2323:249-265. doi: 10.1007/978-1-0716-1499-0_18.
7
fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy.携带载有 miRNA 有效载荷的人源化非编码 RNA 的发酵生产用于靶向抗癌治疗。
Theranostics. 2021 Mar 4;11(10):4858-4871. doi: 10.7150/thno.56596. eCollection 2021.
8
Promoter-based identification of novel non-coding RNAs reveals the presence of dicistronic snoRNA-miRNA genes in Arabidopsis thaliana.基于启动子的新型非编码RNA鉴定揭示了拟南芥中双顺反子snoRNA-miRNA基因的存在。
BMC Genomics. 2015 Nov 25;16:1009. doi: 10.1186/s12864-015-2221-x.
9
Bioengineered RNA Therapy in Patient-Derived Organoids and Xenograft Mouse Models.基于患者来源的类器官和异种移植小鼠模型的生物工程 RNA 疗法。
Methods Mol Biol. 2022;2521:191-206. doi: 10.1007/978-1-0716-2441-8_10.
10
Non-coding RNAs and potential therapeutic targeting in cancer.非编码 RNA 与癌症的潜在治疗靶点
Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188491. doi: 10.1016/j.bbcan.2020.188491. Epub 2020 Dec 13.
引用本文的文献
1
Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy.通过靶向 CD44 的纳米载体抑制 iRhom1 以改善癌症免疫化疗。
Nat Commun. 2024 Jan 4;15(1):255. doi: 10.1038/s41467-023-44572-6.
2
RNA-based drugs and regulation: Toward a necessary evolution of the definitions issued from the European union legislation.基于RNA的药物与监管：迈向欧盟立法所定义的必要演变
Front Med (Lausanne). 2022 Oct 17;9:1012497. doi: 10.3389/fmed.2022.1012497. eCollection 2022.
3
Bioengineered miR-34a modulates mitochondrial inner membrane protein 17 like 2 (MPV17L2) expression toward the control of cancer cell mitochondrial functions.生物工程 miR-34a 通过调节线粒体内膜蛋白 17 样 2（MPV17L2）的表达来控制癌细胞线粒体功能。
Bioengineered. 2022 May;13(5):12489-12503. doi: 10.1080/21655979.2022.2076399.
4
Non-coding RNAs and their bioengineering applications for neurological diseases.非编码 RNA 及其在神经疾病中的生物工程应用。
Bioengineered. 2021 Dec;12(2):11675-11698. doi: 10.1080/21655979.2021.2003667.
5
Baicalin suppresses lung cancer growth phenotypes via miR-340-5p/NET1 axis.黄芩通过 miR-340-5p/NET1 轴抑制肺癌生长表型。
Bioengineered. 2021 Dec;12(1):1699-1707. doi: 10.1080/21655979.2021.1922052.
6
Long non-coding RNA nuclear enriched abundant transcript 1 (NEAT1) sponges microRNA-124-3p to up-regulate phosphodiesterase 4B (PDE4B) to accelerate the progression of Parkinson's disease.长链非编码 RNA 核富集丰富转录本 1（NEAT1）作为 microRNA-124-3p 的海绵体，上调磷酸二酯酶 4B（PDE4B）以加速帕金森病的进展。
Bioengineered. 2021 Dec;12(1):708-719. doi: 10.1080/21655979.2021.1883279.
7
Transcription and Translation Inhibitors in Cancer Treatment.癌症治疗中的转录和翻译抑制剂
Front Chem. 2020 Apr 21;8:276. doi: 10.3389/fchem.2020.00276. eCollection 2020.
8
Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics.生物工程改造的miR-328-3p调节葡萄糖转运蛋白1介导的葡萄糖摄取和代谢，以发挥与化疗药物协同的抗增殖作用。
Acta Pharm Sin B. 2020 Jan;10(1):159-170. doi: 10.1016/j.apsb.2019.11.001. Epub 2019 Nov 7.
9
Novel approaches for efficient in vivo fermentation production of noncoding RNAs.新型高效非编码 RNA 体内发酵生产方法。
Appl Microbiol Biotechnol. 2020 Mar;104(5):1927-1937. doi: 10.1007/s00253-020-10350-3. Epub 2020 Jan 17.
10
Current trends in drug metabolism and pharmacokinetics.药物代谢与药代动力学的当前趋势。
Acta Pharm Sin B. 2019 Nov;9(6):1113-1144. doi: 10.1016/j.apsb.2019.10.001. Epub 2019 Oct 18.
本文引用的文献
1
Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest.基因工程改造的前体微小RNA-34a前药通过诱导凋亡和细胞周期阻滞抑制原位骨肉瘤异种移植肿瘤生长。
Sci Rep. 2016 May 24;6:26611. doi: 10.1038/srep26611.
2
Advances in time course extracellular production of human pre-miR-29b from Rhodovulum sulfidophilum.嗜硫红假单胞菌胞外生产人源前体miR-29b的时间进程研究进展
Appl Microbiol Biotechnol. 2016 Apr;100(8):3723-34. doi: 10.1007/s00253-016-7350-x. Epub 2016 Feb 10.
3
Recombinant pre-miR-29b for Alzheimer´s disease therapeutics.用于阿尔茨海默病治疗的重组前体微小核糖核酸-29b
Sci Rep. 2016 Jan 28;6:19946. doi: 10.1038/srep19946.
4
Bioengineering of noncoding RNAs for research agents and therapeutics.用于研究试剂和治疗的非编码RNA的生物工程。
Wiley Interdiscip Rev RNA. 2016 Mar-Apr;7(2):186-97. doi: 10.1002/wrna.1324. Epub 2016 Jan 13.
5
MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.微小RNA药物表观遗传学：可变药物处置背后的转录后调控机制及开发更有效疗法的策略。
Drug Metab Dispos. 2016 Mar;44(3):308-19. doi: 10.1124/dmd.115.067470. Epub 2015 Nov 13.
6
Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.生物工程化的miR-34a前药与阿霉素联合治疗可协同抑制骨肉瘤生长。
Biochem Pharmacol. 2015 Dec 15;98(4):602-13. doi: 10.1016/j.bcp.2015.10.015. Epub 2015 Oct 27.
7
Genetically modified proteins: functional improvement and chimeragenesis.转基因蛋白：功能改进与嵌合发生
Bioengineered. 2015;6(5):262-74. doi: 10.1080/21655979.2015.1075674. Epub 2015 Jul 25.
8
Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization.用于前体药物癌症治疗的生物工程新型嵌合微小RNA-34a：高产表达、纯化以及结构与功能表征
J Pharmacol Exp Ther. 2015 Aug;354(2):131-41. doi: 10.1124/jpet.115.225631. Epub 2015 May 28.
9
In Vivo Production of Small Recombinant RNAs Embedded in a 5S rRNA-Derived Protective Scaffold.嵌入5S rRNA衍生保护支架中的小重组RNA的体内生产。
Methods Mol Biol. 2015;1316:45-65. doi: 10.1007/978-1-4939-2730-2_5.
10
Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity.在大肠杆菌中高效生物合成的嵌合微小RNA-1291可有效降低人癌细胞中靶基因的表达并提高化学敏感性。
Drug Metab Dispos. 2015 Jul;43(7):1129-36. doi: 10.1124/dmd.115.064493. Epub 2015 May 1.
Zotero 插件